Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Δεν υπάρχει περίληψη
Έτος δημοσίευσης:
2013
Συγγραφείς:
San Miguel, Jesús F Schlag, Rudolf Khuageva, Nuriet K Dimopoulos, Meletios A Shpilberg, Ofer Kropff, Martin Spicka, Ivan Petrucci, Maria Teresa Palumbo, Antonio Samoilova, Olga S others
